Yes there is potential Competing Interest.
The authors declare the following competing interests:
Dr. Abreu has received research funding from the National Institute of Health, Department of Defense, The Leona M. and Harry B. Helmsley Charitable Trust (through the University of Miami), Crohn’s and Colitis Foundation, and Kenneth Rainin Foundation. She is a consultant or served on advisory boards for AbbVie Inc, Arena Pharmaceuticals Inc (now Pfizer), Bristol Myers Squibb, Celsius Therapeutics, Eli Lilly and Company, Gilead Sciences Inc, Janssen Pharmaceuticals, Janssen Global Services, Pfizer Pharmaceutical, Prometheus Biosciences, UCB Biopharma SRL. She has received fees for lecturing from Alimentiv, Janssen Pharmaceuticals, Prime CME, and WebMD Global LLC.
Dr. Balderramo has received speaking fees from AbbVie, Takeda and Janssen, and consulting fees from AbbVie, Takeda, Janssen and Amgen.
Dr. Benchimol has acted as a consultant for McKesson Canada and the Dairy Farmers of Ontario for matters unrelated to medications used to treat inflammatory bowel disease. He has also acted as a consultant for the Canadian Agency for Drugs and Technology in Health (CADTH).
Dr. Bernstein is supported by the Bingham Chair in Gastroenterology. Dr. Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Eli Lilly Canada, JAMP Pharmaceuticals, Janssen Canada, Pendopharm Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Consultant for Takeda; Educational grants from AbbVie Canada, Bristol Myers Squibb Canada, Ferring Canada, Pfizer Canada, Takeda Canada, Janssen Canada, Organon Canada, Eli Lilly Canada and Amgen Canada. Speaker’s panel for AbbVie Canada, Janssen Canada, Pfizer Canada, and Takeda Canada. Received research funding from AbbVie Canada, Amgen Canada, Sandoz Canada, Takeda Canada and Pfizer Canada.
Dr. Brunet-Mas has served as a speaker and consultant for Janssen, Chiesi, Takeda and Kern.
Dr. Burisch reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, and personal fees from Galapagos; outside the submitted work.
Dr. Dotan received consultation fees/served in advisory boards/speakers’ bureaus for AbbVie, Athos, Arena, Celltrion, Celgene/BMS, Eli-Lilly, Ferring, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Janssen, Neopharm, Pfizer, Roche/Genentech, Sangamo, Sublimity, Sandoz, Takeda, Wildbio, and Prometheus. Jill Roberts IBD Center, Shareholder: Gutreat, Harp diagnostics.
Dr. El Ouali has received honoraria for speaking from AbbVie and Janssen.
Dr. Forss has served as a speaker and advisory board member for Janssen corporation and Tillotts Pharma.
Dr. Gearry has received research funding from AbbVie, Janssen, Zespri, Comvita, Goodman Fielder, and Takeda; he has served on advisory boards for AbbVie, Janssen, Zespri, Comvita, and Takeda; and has received honoraria from AbbVie, Janssen, Zespri, and Takeda.
Dr. Hartono has received consultation and speaking fee from Janssen, Ferring, AbbVie, and Takeda.
Dr. Hilmi has received consulting and speaking honoraria from AbbVie, Janssen, Ferring, LF Asia, Pfizer, and Takeda.
Dr. Jones is funded by a Wellcome Trust Clinical Research Career Development Fellowship and has received speaker fees from AbbVie, Ferring Pharmaceuticals, Janssen, Takeda, Fresenius Kabi and Pfizer.
Dr. Juliao-Baños has received consulting and speaking fees from AbbVie, Janssen, Pfizer, Celltrion, and Takeda.
Dr. Kaibullayeva has served on advisory boards for Janssen Kazakhstan and has been a consultant for Takeda and Ferring; has been on speaker panels for Janssen, Takeda, Ferring, Thermo Fisher Scientific; and has received research funding from Ferring Kazakhstan.
Dr. Kaplan has received honoraria for speaking or consultancy from AbbVie, Amgen, Janssen, Pfizer, Sandoz, and Pendophram. Dr. Kaplan received grants for research from Ferring and for educational activities from AbbVie, Bristol Myers Squibb, Ferring, Fresenius-Kabi, Janssen, Pfizer, Takeda. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018.
Dr. Kobayashi has served as an advisory board member, consultant, or speaker for AbbVie, Activaid, Ajinomoto Bio-Pharma, Alfresa Pharma, Alimentiv, Astellas Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, JMDC, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, Thermo Fisher Scientific, and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Takeda, Thermo Fisher Scientific, and Zeria Pharmaceutical.
Dr. Kotze has received consulting and speaking honorarium from AbbVie, Janssen, Pfizer and Takeda. He also has received scientific grants from Pfizer and Takeda.
Dr. Lakatos has been a speaker and/or advisory board member: AbbVie, Amgen, BioJamp, Bristol Myers Squibb, Fresenius Kabi, Genetech, Gilead, Janssen, Merck, Mylan, Organon, Pendopharm, Pfizer, Roche, Sandoz, Takeda, Tillots, and Viatris; and has received unrestricted research grant: AbbVie, Gilead, Takeda, and Pfizer.
Professor Lees is funded by a UK Research and Innovation Future Leaders Fellowship and has acted as a speaker and/or consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung Bioepis, Fresenius Kabi, Tillotts, Trellus Health, and Iterative Health.
Dr. Lo has received speaking fees from Tillotts Pharma and Janssen Cilag; consultancy fee from Tillotts Pharma and Bristol Myers Squib; and received unrestricted research grants from Janssen Cilag, Tillotts Pharma; outside the submitted work.
Professor Loftus has consulted for AbbVie, Alvotech, Amgen, Arena, Astellas, Avalo, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Health, Janssen, Morphic, Ono, Protagonist, Sun, Surrozen, Takeda, TR1X, and UCB; has received research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Takeda, Theravance, and UCB; and is a shareowner of Exact Sciences.
Dr. Siew Ng has served as an advisory board member for Pfizer, Ferring, Janssen, and AbbVie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, AbbVie, and Takeda. She has received research grants through her affiliated institutions from Olympus, Ferring, and AbbVie. Siew Ng is a founder member, non-executive director, non-executive scientific advisor, and shareholder of GenieBiome Ltd. Siew Ng receives patent royalties through her affiliated institutions.
Dr. Okabayashi has received speaking fees from Mitsubishi Tanabe Pharma and consulting fees from EA Pharma.
Dr. Olén has been PI on projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen, Takeda, AbbVie, Pfizer, Bristoll Myers Squibb, and Ferring, and also report grants from Pfizer, AbbVie, Janssen, and Galapagos in the context of a national safety monitoring programs. None of these studies have any relation to the present study. Karolinska Institutet has received fees for lectures and participation on advisory boards by Dr. Olén from Janssen, Ferring, Takeda, and Pfizer on topics not related to the present study.
Dr. Panaccione has received consulting fees from Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda.
Dr. Quaresma has received speaking honorarium from AbbVie, Apsen and Janssen.
Dr. Raja Ali has received speaking and consulting honoraria from AbbVie, Astra Zeneca, Ferring, Pfizer, Janssen and Takeda.
Dr. Rubin has received grant support from Takeda; and has served as a consultant for AbbVie, Altrubio, Amgen, Avalo Therapeutics, Bristol-Myers Squibb, Buhlmann Diagnostics Corp, Chronicles Health, ClostraBio, Connect BioPharma, Cytoki Pharma, Douglas Pharmaceuticals, EcoR1, Ferring Pharma, Image Analysis Group, Index Pharmaceuticals, Iterative Health, Janssen Pharmaceuticals, Lilly, Odyssey Therapeutics, Pfizer, Prometheus Biosciences, Reistone Biopharma, Samsung Neurologica, Sangamo Therapeutics, Shanghai Pharma Biotherapeutics USA, Takeda, Tissium S.A., and Trellus Health.
Dr. Suzuki has received honoraria for speaking from Astellas, AbbVie, Biofermin, EA Pharma, Janssen, Kissei, Miyarisan, Otsuka, Tanabe-Mitsubishi, Takeda, Tsumura, and Viatris. Dr. Suzuki received grants for research from Toh-so and Biofermin.
Dr. Toro has received consulting and speaking fees from AbbVie, Janssen, and Takeda.
Dr. Turner received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, Shaare Zedek Medical Center, Hospital for Sick Children, Ferring, AbbVie, Takeda, Prometheus Biosciences, Lilly, Roche, ThermoFisher, BMS, SorrisoPharma.
Dr. Vergara has been member of advisory boards for AbbVie, Janssen, and Takeda.
Dr. Wei has received consultancy fees from AbbVie, Bristol-Myers Squibb, Celltrion, Ferring Pharmaceuticals Inc., Janssen, Pfizer Inc, Takeda, and Tanabe, and speaker fees from AbbVie, Bristol-Myers Squibb, Celltrion, Excelsior Biopharma Inc., Ferring Pharmaceuticals Inc., Pfizer Inc, Janssen, Sanofi, Takeda and Tanabe.
Dr. Yamamoto-Furusho is a speaker bureau member for AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein, Takeda; is a clinical research investigator Bristol Myers Squibb, Takeda has been member of advisory boards for AbbVie, Celltrion, Ferring, Janssen, Takeda; has received research grants from Takeda; payments for lectures from AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein, Takeda; and is an advisory board member of the AbbVie, Celltrion, Ferring, Janssen, Takeda.
No competing interests: Dr. Yvonne Abbey, Dr. Murdani Abdullah, Dr. Vineet Ahuja, Dr. Mansour Altuwaijri, Dr. Rupa Banerjee, Michael Buie, Léa Caplan, Dr. Vui Heng Chong, Dr. Stephanie Coward, Dr. Michael Cummings, Dr. Viet Hang Dao, Dr. Usha Dutta, Angela Forbes, Quinn Goddard, Julia Gorospe, Dr. Phoebe Hodges, Dr. Lindsay Hracs, Dr. Paul Kelly, Dr. Julajak Limsrivilai, Dr. Jonas F. Ludvigsson, Dr. Joyce WY Mak, Ante Markovinović , Dr. YingLei Miao, Dr. Ka Kei Ng, Dr. Mukesh Sharma Paudel, Joshua Quan, Dr. Marcellus Simadibrata, Dr. Yang Sun, Dr. Tyler Williamson, Dr. Joseph W. Windsor, and Dr. Suk-Kyun Yang.